| 1 |
Partly verified |
Full text not readStored summary read |
N01 · Comparative efficacyAre the original DunedinPACE subclaim assessment and the parent pace-of-aging context kept separate?Required |
The subclaim concerns 'Slower DunedinPACE', with original grade C and a note of a roughly 2~3% slowing signal. The parent surrogate assessment is C, 54 points and Unknown safety. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The subclaim has no score, status or axes; parent values are not used to fill them. This is not a new clinical assessment. |
Separate records of the original claim, grade, note and parent values |
If additional original material is provided, connect the selected measure separately from the parent context. |
| 2 |
Partly verified |
Full text not readStored summary read |
N02 · Comparative efficacyWhat population and applicability limits concern healthy non-obese adults?Required |
The original population was healthy non-obese adults, and CALERIE took place at three US sites. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Detailed age, BMI, disease and eligibility criteria are absent from this summary. Findings are not automatically applied to aging or disease effects in other populations. |
Age, baseline condition, obesity status, eligibility and population-specific denominators |
Obtain original eligibility, baseline characteristics and recruitment denominators. |
| 3 |
Partly verified |
Full text not readStored summary read |
N03 · Comparative efficacyAre the target caloric restriction and achieved average exposure distinguished?Required |
The historical study target was 25% restriction, whereas the original account reports average achieved restriction of about 12%. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The target and achieved exposure are not treated as identical or presented as personal dietary, calorie or weight-loss targets. Individual exposure, estimation and changes over time have not been read. |
Study records of the original target, achieved exposure, measurement, adherence and duration |
Obtain original exposure measurements, adherence, support and change records. |
| 4 |
Partly verified |
Full text not readStored summary read |
N04 · Comparative efficacyCan the intervention and control diets, support and concurrent exposures over two years be verified?Required |
The original intervention was two-year caloric restriction, and the positive finding is recorded as a randomized comparison with a control group. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Specific control diets, contact, support and concurrent management are absent from this summary. Equivalent calorie, nutrient or attention conditions are not newly confirmed. |
Actual intervention and control diets, support, contact and concurrent management |
Connect protocol records of the control, support, achieved exposure and concurrent management. |
| 5 |
Partly verified |
Full text not readStored summary read |
N05 · Comparative efficacyDo 220 randomized participants, 2:1 allocation and the 197-person DNA sample share a denominator?Required |
CALERIE randomized 220 participants in a 2:1 ratio. DNA data were analyzed for 197 participants with baseline and at least one follow-up sample. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Group sizes are not newly calculated from the allocation ratio. The 197 participants are not assumed to be the denominator for every measure at both 12 and 24 months. |
Randomization, sample acquisition, measure-specific analyses and time-specific denominators |
Obtain original tables tracing allocation, DNA samples and analyses by time and measure. |
| 6 |
Partly verified |
Full text not readStored summary read |
N06 · Comparative efficacyDo gaps remain concerning DNA sample selection, follow-up, missingness and the effect of interest?Required |
The original DNA analysis requirement of baseline and at least one follow-up sample is preserved. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Reasons for DNA exclusions, missingness by time, ITT status and sample-selection effects have not been read. Attrition rates or missing counts are not newly calculated. |
Sample selection, missingness by group, analysis populations, sensitivity analyses and original models |
Obtain original sample-selection, group-specific missingness, analysis-population and sensitivity plans. |
| 7 |
Partly verified |
Full text not readStored summary read |
N07 · Comparative efficacyIs DunedinPACE a pace measure distinct from clinical events?Required |
The original account describes DunedinPACE as a DNA-methylation measure of the pace of aging and a surrogate rather than a clinical event. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The result is not converted into clinical aging itself, reduced disease, rejuvenation or years of life. Details of the formula, units and clinical calibration have not been read. |
DNA measure definitions, measurement units, validation and measurement procedures |
Obtain original measure definitions, validation, measurement, units and clinical-linkage material. |
| 8 |
Unverified |
Full text not readStored summary read |
N08 · Comparative efficacyAre details of DNA measurement, batches, normalization and measure calculation available?Required |
The post hoc DNA-methylation design and analyst blinding are preserved. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Sample types, laboratory platforms, batches, normalization and algorithm details are not inferred, and measures are not newly calculated. |
Original methods for samples, DNA measurement, batches, normalization and algorithms |
Obtain original laboratory, measure-calculation and quality-processing methods. |
| 9 |
Partly verified |
Full text not readStored summary read |
N09 · Comparative efficacyAre the original 12-month DunedinPACE effect and CI preserved?Required |
The original account records the 12-month effect as d=−0.29 (95% CI −0.45 to −0.13). |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The standardized effect d is not recalculated into years of aging, percentages or clinical-event effects. Time-specific group denominators and model details have not been read. |
Original effects, units, CIs, models and denominators by time |
Obtain the original 12-month model, adjustments, denominators, effect and CI. |
| 10 |
Partly verified |
Full text not readStored summary read |
N10 · Comparative efficacyIs the 24-month DunedinPACE effect and interval preserved as a separate time-specific value?Required |
The original wording d=−0.25 (−0.41 to −0.09) at 24 months is preserved. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The 12-month 95% label is not added to the 24-month interval without separate verification in the original paper. A mean of the two time points or a persistence rate is not calculated. |
Original effects, original intervals, models and denominators by time |
Obtain the original 24-month effect, interval level, model and time-specific denominators. |
| 11 |
Partly verified |
Full text not readStored summary read |
N11 · Comparative efficacyWhat is the scope of P<0.003 and the roughly 2~3% wording?Required |
The original rationale presents the DunedinPACE values at 12 and 24 months together with P<0.003. The reader answer and note describe roughly 2~3% slowing. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The P threshold is not turned into separate exact values for each time point, and 2~3% is not newly calculated from d. It is not converted into a rate of longer healthy life. |
Links between time-specific tests, effect transformations and original estimates |
Obtain the original definitions and models for time-specific tests and percentage wording. |
| 12 |
Partly verified |
Full text not readStored summary read |
N12 · Comparative efficacyAre the null PC PhenoAge and PC GrimAge findings preserved together?Required |
The original account describes the other two measures as null, with d −0.04 to 0.05 and P>0.15. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The range endpoints are not assigned separately to individual measures or time points. The finding is not extended to slowing of all DNA clocks. |
Original effects, intervals and tests by distinct measure and time |
Obtain effects, CIs, P values and denominators separately for each PC measure and time. |
| 13 |
Partly verified |
Full text not readStored summary read |
N13 · Comparative efficacyDo the pace measure and the two PC clocks use the same units and address the same question?Required |
The original account distinguishes a result in which only one of three DNA-methylation measures changed. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The pace-measure effect is not copied as an effect or value for PC biological age. Exact differences in units and validation have not been read. |
Definitions, reference standards, units and interpretation limits for each measure |
Obtain original definitions, validation, units and applicability material for each measure. |
| 14 |
Partly verified |
Full text not readStored summary read |
N14 · Comparative efficacyAre the post hoc analysis and the parent's prespecified clinical primary endpoint distinguished?Required |
The paper explicitly identifies the analysis as post hoc. The original account states that the DNA outcomes were not the parent trial's prespecified clinical primary endpoint. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The DNA analysis is not recast as a prespecified confirmatory primary analysis merely because its parent trial was randomized. |
Original registration, protocol, SAP, analysis timing and outcome hierarchy |
Obtain original registration, protocol and SAP, and records of post hoc analysis selection and changes. |
| 15 |
Partly verified |
Full text not readStored summary read |
N15 · Comparative efficacyAre the split findings across three measures and the multiple-outcome analysis plan preserved?Required |
The original account assesses only one of three measures as positive and the key measures as split; the parent split-key-measures flag remains true. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The parent's split-results wording is not turned into a new claim that all three measures were the parent's clinical coprimary endpoints. Multiplicity-adjustment details have not been read. |
Original plans for three measures, time points, models, tests and multiplicity handling |
Obtain the DNA analysis's original outcome list, time points, tests, adjustments and selective-reporting plan. |
| 16 |
Partly verified |
Full text not readStored summary read |
N16 · Comparative efficacyIs the absence of a clinical minimum-effect threshold and prespecified success boundary preserved?Required |
The original account records no clinical minimum-effect threshold or prespecified success boundary and describes the effects as small. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Statistical positivity is not converted into certification of general clinical importance, calorie targets or health effects. |
Clinical validation, minimum-effect thresholds and plans for each measure |
Connect clinical validation, prespecified thresholds and plans for each measure if provided. |
| 17 |
Partly verified |
Full text not readStored summary read |
N17 · Comparative efficacyWhat is the original scope of allocation and analyst blinding?Required |
The Korean account says that analysts did not know allocation; the English account specifies 'laboratory analysts blinded'. The parent's 2:1 randomized design is also preserved. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Blinding of all analysts, participants or intervention providers is not newly certified. Allocation concealment and measure-specific model procedures have not been read. |
Parent allocation, blinding of DNA laboratory staff or analysts, and analysis procedures |
Obtain original allocation, laboratory and measure-analysis methods and blinding roles. |
| 18 |
Unverified |
Full text not readStored summary read |
N18 · Comparative efficacyIs the relationship between achieved restriction, adherence, weight changes and measure effects directly verified?Required |
The 25% target and average achieved restriction of about 12% are preserved as historical study conditions. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Effects of individual achieved restriction, time-specific adherence and weight or nutrient mediation are not newly calculated or confirmed as causal mechanisms. |
Original achieved exposure, adherence, concurrent changes and effects of interest |
Obtain achieved exposure, adherence, concurrent changes and prespecified mediation or effect-of-interest material. |
| 19 |
Unverified |
Full text not readStored summary read |
N19 · Comparative efficacyDo gaps remain concerning persistence after 12 or 24 months, mechanisms and other aging measures?Required |
The original DNA effects are presented at 12 and 24 months, and the intervention lasted two years. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Persistence after the intervention or effects on all aging mechanisms and later measures are not newly filled in. |
Follow-up measures, duration, denominators, original effects and direct mechanism evidence |
Obtain direct post-intervention follow-up and original measurements, denominators and effects separately by measure. |
| 20 |
Partly verified |
Full text not readStored summary read |
N20 · Comparative efficacyHas the result been kept separate from disease, disability, death, lifespan and independent-living outcomes?Required |
The original account explicitly states that reduced disease, disability or death was not measured and longer healthy life was not answered. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The slowing signal is not turned into proof of clinical rejuvenation, added years of life or maintained independent living. |
Direct clinical endpoints, adequate follow-up, events, denominators and effects |
Direct definitions, long-term follow-up, denominators and effect data are needed for each clinical outcome. |
| 21 |
Partly verified |
Full text not readStored summary read |
N21 · Comparative efficacyAre the two sibling sheets, two time points and one post hoc report kept from being independently summed?Required |
Both sheets share the same CALERIE post hoc report and the 220-person and 197-person context. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Reports, measures and time points are not summed as new independent trials or participant totals. Unique trial and participant totals and the final independent count remain unrecorded. |
Relationships among the parent trial, post hoc report, same participants, measures and time points |
Link additional reports through original trial identifiers while retaining relationships to the same population. |
| 22 |
Partly verified |
Full text not readStored summary read |
N22 · Comparative efficacyAre funding and DunedinPACE invention and commercial-licensing interests distinguished?Required |
Support from NIA, American Brain Foundation, CIHR and others, authorship by inventors D.L. Corcoran and D.W. Belsky, and commercial licensing are preserved. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Inventors are not newly classified as company employees or financial beneficiaries. Details of cash funding, provision, affiliations and outside analysis have not been read. |
Funding, authors, invention, licensing, provision and analysis roles |
Obtain original funding, licensing, affiliations, product or service provision, analysis and manuscript roles separately. |
| 23 |
Partly verified |
Full text not readStored summary read |
N23 · Supplementary harm evidenceDoes absent safety reporting establish that the parent trial had no harms?Required |
This post hoc analysis did not report safety as an endpoint, and the parent's safety assessment is Unknown. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Absent reporting in the post hoc report is not extended to zero adverse events or established safety across CALERIE. |
Harm plans, events by group and exposure denominators for this analysis and the parent trial |
Obtain the parent trial's original harm plans, events by group, exposure, discontinuation and denominators separately. |
| 24 |
Unverified |
Full text not readStored summary read |
N24 · Supplementary harm evidenceDo gaps remain concerning long-term or rare harms under two-year achieved exposure?Required |
The original safety account states that this analysis cannot determine harms of long-term caloric restriction. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Duration alone does not establish safety, and new harm counts, rates, CIs or nutritional problems are not invented. |
Direct harm data by achieved exposure, discontinuation, severity and duration |
Obtain group-specific harms, discontinuation, rare events and long-term data from the parent trial and follow-up reports. |
| 25 |
Unverified |
Full text not readStored summary read |
N25 · Supplementary harm evidenceAre harm replication, applicability to other populations or exposures, and dietary instructions distinguished?Required |
The current population is healthy non-obese adults, and the historical exposure is a two-year study with differing target and achieved average restriction. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. Effects or harms in other populations or dietary-restriction methods are not newly confirmed, and personal calorie, diet or weight-loss instructions are not created. |
Direct effects, harms, exposures and same-population relationships by population |
Connect direct comparisons and harm evidence for new populations or exposures separately. |
| 26 |
Partly verified |
Full text not readStored summary read |
N26 · Comparative efficacyAre the stored summary, PubMed link and registration identifier distinguished from materials actually read?Required |
The whole parent summary was read for production, and the original PubMed link and NCT00427193 identifier were connected. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. A new registration URL is not constructed from the identifier; all external materials remain unread. Links and original full text were not compared or tested. |
Separate access records for the summary, abstract, full text, registration, protocol and SAP |
Connect additional provided material with its individual access status. |
| 27 |
Partly verified |
Full text not readStored summary read |
N27 · Comparative efficacyAre original dates, Korean and English text, empty values, subclaim and parent values, and review status preserved?Supplementary |
The 2026-08-26 reference date, empty correction and deliberation values, Korean and English text, C54, original axes and subclaim C are preserved. Original pending and production-eligible markers are historical; content review at that time remained incomplete. |
Only the relevant information from the stored summary is recorded. Detailed original materials have not been read, and the original content review remains incomplete. The missing subclaim score and unrecorded precision are not filled in. Original model, content and scope review activation and completion remain false; added assessment units are 0 and the final independent count is unrecorded. |
Distinction among the complete original, selected assessment record, history and current production status |
Proposal: Reflect additional materials and decisions through preservation of original wording and separate events. |